Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia

被引：6

作者：

Kinjyo, Ichiko ^{[1
]}

Matlawska-Wasowska, Ksenia ^{[2
,3
]}

Chen, Xiaoru ^{[4
]}

Monks, Noel R. ^{[5
]}

Burke, Patricia ^{[4
]}

Winter, Stuart S. ^{[2
,3
]}

Wilson, Bridget S. ^{[1
,2
]}

机构：

[1] Univ New Mexico, Dept Pathol, Hlth Sci Ctr, Albuquerque, NM 87131 USA

[2] Univ New Mexico, Ctr Canc, Hlth Sci Ctr, Albuquerque, NM 87131 USA

[3] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Div Hematol Oncol, Albuquerque, NM 87131 USA

[4] MedImmune, Translat Med Oncol, Gaithersburg, MD USA

[5] MedImmune, Oncol Res, Gaithersburg, MD USA

来源：

PEDIATRIC BLOOD & CANCER | 2017年 / 64卷 / 11期

关键词：

acute lymphoblastic leukemia; immunotherapy; HEMATOLOGIC MALIGNANCIES; PSEUDOMONAS EXOTOXIN; IMMUNOTOXIN; CAT-8015; TRIAL; HA22; CD22;

D O I：

10.1002/pbc.26604

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rg(null) mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient-derived xenograft models.

引用

页数：4

共 50 条

[21] A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia
Short, Nicholas J.
Kantarjian, Hagop
Jabbour, Elias
Cortes, Jorge E.
Thomas, Deborah A.
Rytting, Michael E.
Daver, Naval
Alvarado, Yesid
Konopleva, Marina
Kebriaei, Partow
Wierda, William G.
DiNardo, Courtney D.
Bivins, Carol
McCue, Deborah
Richie, Mary A.
Ravandi, Farhad
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (03) : 442 - 444
[22] CD33+ B-CELL PRECURSOR ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDREN - A DISTINCT SUBGROUP OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC-LEUKEMIA
HARA, J
HOSOI, G
OKAMURA, T
OSUGI, Y
ISHIHARA, S
YUMURAYAGI, K
KAWAHA, K
TAWA, A
INTERNATIONAL JOURNAL OF HEMATOLOGY, 1995, 61 (02) : 77 - 84
[23] PREVALENCE AND CLINICAL CHARACTERIZATION OF CD20 AND CD22 EXPRESSION IN PEDIATRIC PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Rayburg, Melissa S.
Marmer, Daniel
Mo, Jun
McMasters, Richard
Smolarek, Teresa
Lampkin, Beatrice
Perentesis, John
PEDIATRIC BLOOD & CANCER, 2009, 52 (06) : 718 - 718
[24] CD22 AS A TARGET FOR ELIMINATION OF THE LEUKEMIC BLASTS IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Kanderova, V.
Kuzilkova, D.
Vaskova, M.
Kalina, T.
Hrusak, O.
Mejstrikova, E.
HAEMATOLOGICA, 2015, 100 : 342 - 342
[25] Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B Cell Acute Lymphoblastic Leukemia
Yoshida, Sakiko
Tuscano, Emily
Duong, Connie
Tuscano, Joseph
Satake, Noriko
BLOOD, 2014, 124 (21)
[26] Use of Blinatumomab for Relapse Therapy of B-Cell Precursor Acute Lymphoblastic Leukemia
Pawinska-Wasikowska, K.
Wyrobek, E.
Klekawka, T.
Luszawska-Kutrzeba, T.
Garus, K.
Pietrys, D.
Zaniewska-Tekieli, A.
Wieczorek, A.
Balwierz, W.
PEDIATRIC BLOOD & CANCER, 2019, 66 : S251 - S251
[27] Targeted Therapy for ETV6-RUNX1-Driven B-Cell Precursor Acute Lymphoblastic Leukemia
Polak, Roel
Bierings, Marc B.
van der Leije, Cindy S.
van den Dungen, Rosanna E. S.
Sanders, Mathijs A.
Roovers, Onno
Cornelissen, Jan J.
Marchante, Joao R. M.
Pieters, Rob
den Boer, Monique L.
Buitenhuis, Miranda
BLOOD, 2014, 124 (21)
[28] Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia
Huang, Liang
Wang, Na
Li, Chunrui
Cao, Yang
Xiao, Yi
Xiao, Min
Zhang, Yicheng
Zhang, Tongcun
Zhou, Jianfeng
BLOOD, 2017, 130
[29] BL22, an anti-CD22 recombinant immunotoxin, is active in vitro and in vivo against B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells from pediatric patients.
Lew, G
Gu, LB
Zhou, MX
Kreitman, RJ
FitzGerald, DJ
Pastan, I
Woods, WG
Findley, HW
BLOOD, 2002, 100 (11) : 764A - 764A
[30] Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines
Stanciu-Herrera, C.
Morgan, C.
Herrera, L.
LEUKEMIA RESEARCH, 2008, 32 (04) : 625 - 632

← 1 2 3 4 5 →